Last reviewed · How we verify
Semaglutide L
At a glance
| Generic name | Semaglutide L |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Diarrhoea
- Nasopharyngitis
- Vomiting
Key clinical trials
- Effects of Semaglutide in HIV-Associated Lipohypertrophy (PHASE2)
- Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study (PHASE4)
- A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) (PHASE3)
- A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV (PHASE1)
- Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes (PHASE4)
- Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome (PHASE4)
- A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide L CI brief — competitive landscape report
- Semaglutide L updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI